| Title | SARS-CoV-2 infection causes dopaminergic neuron senescence. |
| Publication Type | Journal Article |
| Year of Publication | 2024 |
| Authors | Yang L, Kim TWan, Han Y, Nair MS, Harschnitz O, Zhu J, Wang P, Koo SYeon, Lacko LA, Chandar V, Bram Y, Zhang T, Zhang W, He F, Pan C, Wu J, Huang Y, Evans T, van der Valk P, Titulaer MJ, Spoor JKH, O'Brien RLFurler, Bugiani M, Van de Berg WDJ, Schwartz RE, Ho DD, Studer L, Chen S |
| Journal | Cell Stem Cell |
| Date Published | 2024 Jan 10 |
| ISSN | 1875-9777 |
| Abstract | COVID-19 patients commonly present with signs of central nervous system and/or peripheral nervous system dysfunction. Here, we show that midbrain dopamine (DA) neurons derived from human pluripotent stem cells (hPSCs) are selectively susceptible and permissive to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection of DA neurons triggers an inflammatory and cellular senescence response. High-throughput screening in hPSC-derived DA neurons identified several FDA-approved drugs that can rescue the cellular senescence phenotype by preventing SARS-CoV-2 infection. We also identified the inflammatory and cellular senescence signature and low levels of SARS-CoV-2 transcripts in human substantia nigra tissue of COVID-19 patients. Furthermore, we observed reduced numbers of neuromelanin+ and tyrosine-hydroxylase (TH)+ DA neurons and fibers in a cohort of severe COVID-19 patients. Our findings demonstrate that hPSC-derived DA neurons are susceptible to SARS-CoV-2, identify candidate neuroprotective drugs for COVID-19 patients, and suggest the need for careful, long-term monitoring of neurological problems in COVID-19 patients. |
| DOI | 10.1016/j.stem.2023.12.012 |
| Alternate Journal | Cell Stem Cell |
| PubMed ID | 38237586 |
